These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 19339897)

  • 1. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
    Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor.
    Domingo P; Sambeat MA; Pérez A; Ordoñez J; Rodriguez J; Vázquez G
    Antivir Ther; 2003 Jun; 8(3):223-31. PubMed ID: 12924539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
    Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
    Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevalence of metabolic complications after 10 years of antiretroviral treatment in Senegal].
    Diouf A; Cournil A;
    Bull Soc Pathol Exot; 2014 Oct; 107(4):234-7. PubMed ID: 24683016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.
    Bhutia E; Hemal A; Yadav TP; Ramesh KL
    Afr Health Sci; 2014 Jun; 14(2):408-13. PubMed ID: 25320591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy.
    Mutimura E; Stewart A; Rheeder P; Crowther NJ
    J Acquir Immune Defic Syndr; 2007 Dec; 46(4):451-5. PubMed ID: 18077834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome.
    Soares LR; da Silva DC; Gonsalez CR; Batista FG; Fonseca LA; Duarte AJ; Casseb J
    Rev Inst Med Trop Sao Paulo; 2015; 57(2):105-10. PubMed ID: 25923888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lipodystrophy and echographic hepatic steatosis in HIV-positive patients under highly active antiretroviral therapy (HAART) in Yaounde (Cameroon)].
    Ongolo-Zogo P; Nkodo Mbia N; Mvogo Minkala TL; Biwole Sida M; Kouanfack C; Nko Amvene S
    Bull Soc Pathol Exot; 2012 Dec; 105(5):353-60. PubMed ID: 22886433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study.
    Cames C; Pascal L; Ba A; Mbodj H; Ouattara B; Diallo NF; Msellati P; Mbaye N; Sy Signate H; Blanche S; Diack A;
    BMC Infect Dis; 2018 Aug; 18(1):374. PubMed ID: 30081838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy.
    Vigouroux C; Maachi M; Nguyên TH; Coussieu C; Gharakhanian S; Funahashi T; Matsuzawa Y; Shimomura I; Rozenbaum W; Capeau J; Bastard JP
    AIDS; 2003 Jul; 17(10):1503-11. PubMed ID: 12824788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.
    Piloya T; Bakeera-Kitaka S; Kekitiinwa A; Kamya MR
    J Int AIDS Soc; 2012 Jul; 15(2):17427. PubMed ID: 22814353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.
    Joly V; Flandre P; Meiffredy V; Leturque N; Harel M; Aboulker JP; Yeni P
    AIDS; 2002 Dec; 16(18):2447-54. PubMed ID: 12461419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy.
    Asensi V; Martín-Roces E; Carton JA; Collazos J; Maradona JA; Alonso A; Medina M; Aburto JM; Martínez E; Rojo C; Bustillo E; Fernández C; Arribas JM
    Clin Infect Dis; 2004 Jul; 39(2):240-7. PubMed ID: 15307034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.
    Sánchez Torres AM; Munoz Muniz R; Madero R; Borque C; García-Miguel MJ; De José Gómez MI
    Eur J Pediatr; 2005 May; 164(5):271-6. PubMed ID: 15650834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipodystrophy and metabolic complications of highly active antiretroviral therapy.
    Parakh A; Dubey AP; Kumar A; Maheshwari A
    Indian J Pediatr; 2009 Oct; 76(10):1017-21. PubMed ID: 19907933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.